| |
Join Us
 Interested in a job at Signum? Visit our job postings section for a listing of our open positions. |
|
|
|
Signum's Scientific Advisory Board
Signum has assembled a group of experienced and distinguished experts to provide it with critical counsel and feedback about the company's strategy and its execution of that strategy. The diverse nature of Signum's planned product lines, its innovative fusion of pharmaceutical and consumer research, its divergent marketing challenges, and its heavy reliance on collaborations and partnerships make it critical for the company to have timely access to critical strategic thinkers with broad interdisciplinary experience, and a familiarity with Signum's larger strategy.
General Advisory Board
GPM Scientific Advisors
PPM Scientific Advisors
Thomas Shenk, PhD
Advisory Board Chairman
Thomas is the Elkins Professor of Molecular Biology at Princeton University. He is a member of the National Academy of Sciences and a past president both of the American Academy of Microbiology and the American Society for Virology. He serves on the Board of Directors of Merck & Co. and Cell Genesys.
Back to top
George Kooluris
George spent over 30 years with Bristol-Myers Squibb, most recently as Senior Vice President of Corporate Development. At BMS, he was responsible for some 150 mergers, acquisitions, joint ventures and divestitures worldwide including the merger of Bristol Myers with Squibb and the sale of Clairol to Procter & Gamble.
Back to top
Arshad Zakaria
Arshad was Executive VP and Chairman of the Global Markets and Investment Banking Group at Merrill Lynch until 2004 when he founded New Vernon Capital, a hedge fund that has since grown to $1 B in assets. He received his MBA from Harvard and is on the Board of Directors of The NASDAQ Stock Market and the Cancer Institute of New Jersey.
Back to top
Carl Ehmann, MD
Carl has served as the Director of Clinical Research in Dermatology at Hoffmann-La Roche, as the VP of Pharmaceutical Research and Development for Dermatology at Bristol Myers, as the Executive VP of Consumer Products Worldwide at Johnson & Johnson, and as the President of Reynolds Technologies. He is currently on the Board of Directors of Barrier Therapeutics.
Back to top
Richard Granstein, MD
Richard, the George Hambrick Professor of Dermatology at Cornell, has chaired the Department of Dermatology at the Cornell Weill Medical Center and been Dermatologist-in-Chief at the New York Weill Cornell Medical Center of New York-Presbyterian Hospital since 1995. Previously, he was on the faculty of the Harvard Medical School. His research and clinical interests include autoimmune disorders, skin cancer and psoriasis.
Back to top
John Seykora , MD, PhD
John received his PhD from Rockefeller University and his MD from Cornell University Medical College. He is currently an assistant professor University of Pennsylvania (Dermatology Department), where his lab characterizes the molecular mechanisms that keratinocytes use to regulate growth and differentiation. Also, utilizing microarrays, Dr. Seykora’s lab is characterizing molecular features of normal and diseased human tissue.
Back to top
Diane Thiboutot , MD
Diane is a Professor of Dermatology at Penn State Milton S. Hershey Medical Center. She is recognized for her research in the regulation of sebum production and the treatment of acne. The goal of her research is to determine the mechanisms by which retinoids induce apoptosis in human sebaceous glands. Her translational studies use both cell culture and samples from patients treated for their severe acne. Diane also serves as a reviewer for the National Institute of Health (NIH) as well as several dermatology journals.
Back to top
Jeffrey Cummings, MD
Jeffery is the Augustus S. Rose Professor of Neurology and is also Professor of Psychiatry and Biobehavioral Sciences at UCLA. He is Founder and Director of the UCLA Alzheimer’s Disease Center and directs the UCLA Behavioral Neuroscience and Dementia Research Fellowship. Many of the approximately 40 fellows that he has trained currently hold leadership positions in dementia programs throughout the United States and the world. He is the Founder and Director of the Deane F. Johnson Center for Neurotherapeutics at UCLA. Jeffrey's interests embrace clinical trials and the development of new treatments for neurodegenerative disorders and other neurological diseases. He is past president of the Behavioral Neurology Society and of the American Neuropsychiatric Association and in 2005 was named Edward Henderson State-of-the-Art Lecturer by the American Geriatrics Society. He has authored or edited 20 books and over 450 peer reviewed papers.
Back to top
Khalid Iqbal, PhD
Khalid received his PhD in Biochemistry from the University of Edinburgh, where he carried out pioneering research on Alzheimer neurofibrillary degeneration. He is currently Professor and Chairman, Department of Neurochemistry, at the New York State Institute for Basic Research in Staten Island, New York and co-founded the biennial International Conferences on Alzheimer’s Disease & Related Disorders, (ICAD). Dr. Iqbal has authored over 200 scientific papers in prestigious American and international scientific journals and edited eight books on research advances in Alzheimer’s Disease. His major research interests are the neurobiology of Alzheimer disease and related neurodegenerative disorders, especially the molecular mechanisms of neurofibrillary degeneration, a specific type of nerve cell death which predominates Alzheimer disease and related disorders. His pioneering studies on neuronal protein pathology and discoveries of the involvement of the tau protein and its abnormal hyperphosphorylation in Alzheimer disease have won him several prestigious honors and awards, including the Potamkin Prize from the American Academy of Neurology and the Zenith Award from the Alzheimer’s Association, U.S.A.
Back to top
Yigong Shi, PhD
Yigong, a Professor of Molecular Biology at Princeton University, is a prolific x-ray crystallographer and a leading expert on structure-function relationships in apoptosis. He was a founder of Gentara Corporation and is a member of the company’s Scientific Advisory Board.
Back to top
Scott Vafai, MD
Scott is a graduate of Harvard Medical School currently training in internal medicine at Brigham and Women's Hospital. As an undergraduate at Princeton, he worked with Dr. Jeffry Stock to develop a model linking PP2A methylation to Alzheimer's disease pathogenesis. He continues to work with Signum to develop therapeutics targeting the PP2A methylation system.
Back to top
Lynn Enquist, PhD
Lynn Enquist, PhD, the Chair of the Department of Molecular Biology at Princeton University is Editor-in-Chief of the Journal of Virology, President of the American Society for Virology, and a member of the AAAS board of directors. He also was commissioner of the New Jersey Cancer Commission and has led a variety of corporate and government research programs.
Back to top
Howard Stevenson, PhD
Howard Stevenson, PhD, chairs the Owner/President Program in Executive Training at Harvard Business School, where he is the Sarofim-Rock Professor of Business Administration, a chair established to provide for research and teaching of entrepreneurship. He has authored, edited or co-authored six books including: New Business Ventures and the Entrepreneur and Do Lunch or Be Lunch.
Back to top
Zoe Draelos, MD
Dr. Draelos serves on the board of directors for the American Academy of Dermatology and has a research interest in cosmetics, toiletries, and biologically active skin medications. Dr. Draelos is a practicing, board certified dermatologist in High Point, North Carolina, and editor of multiple dermatology publication.
Back to top
Emmanuel Planel, PhD
Dr. Planel is an Assistant Professor, Centre Hospitalier de l'Université Laval (Québec), and was recently an Adjunct Assistant Professor at Columbia University’s Taub Institute for Research. He worked with Dr. Karen Duff, a leader in Alzheimer’s disease and tauopathy research. Dr. Planel investigates the mechanisms of hypothermia-induced tau hyperphosphorylation and its relevance to cognitive impairment, dementia and neurodegeneration. He has extensive experience developing and validating animal models of neurodegeneration.
Back to top
|
|
